[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"free-flap\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:free-flap":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100643524","phase-4-comparing-intraoperative-indocyanine-green-fluorescence-imaging-with-standard-clinical-assessment-for-flap-perfusion-in-head-and-neck-reconstruction-vision-trial-100643524",false,"NCT07635420","Comparing Intraoperative Indocyanine Green Fluorescence Imaging With Standard Clinical Assessment for Flap Perfusion in Head and Neck Reconstruction (VISION Trial)","Comparing Intraoperative Indocyanine Green Fluorescence Imaging With Standard Clinical Assessment for Flap Perfusion in Head and Neck Reconstruction: A Randomised Controlled Trial (VISION Trial)","VISION","Inclusion Criteria:\n\n* Age ≥18 years at the time of inclusion\n* Scheduled to undergo microvascular free flap reconstruction as part of oncologic, trauma, or benign surgery in the head and neck area\n* Ability to understand study information and provide written informed consent\n\nExclusion Criteria:\n\n* Known allergy to indocyanine green or iodine\n* Severe hepatic or renal impairment\n* Confirmed or suspected pregnancy\n* Breastfeeding","ALL","18 Years",{"count":20,"type":21},244,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","This is a prospective multicentre randomised controlled trial evaluating whether intraoperative indocyanine green (ICG) fluorescence angiography improves outcomes in head and neck free flap reconstruction compared with standard clinical assessment of flap perfusion. Adult patients undergoing microvascular free flap reconstruction for oncologic, trauma, or benign head and neck defects will be randomised to either intraoperative ICG angiography or conventional clinical perfusion assessment. The primary outcome is partial flap loss requiring intervention within 30 days after surgery. Secondary outcomes include total flap loss, flap-related re-exploration, flap salvage, and postoperative complications.",[27,28,29,30,31,32,33,34],"Head and Neck Cancer (H&N)","Free Tissue Flaps","Free Flap","Free Flap Evaluation","Indocyanine Green","Indocyanine Green (ICG)","Microsurgery","Randomised Controlled Trial","NOT_YET_RECRUITING","2026-06-08",{"date":38,"type":39},"2026-06-09","ACTUAL",{"date":41,"type":21},"2026-10-01",{"date":43,"type":21},"2029-08-01",{"name":45,"class":46},"Region Skane","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":59,"conditions":60,"keywords":65,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":47},"100628835","resection-and-defect-repair-of-oral-cancer-aided-by-mixed-reality-technology-100628835","NCT07466810","Resection and Defect Repair of Oral Cancer Aided by Mixed Reality Technology","Prospective Clinical Study in Resection and Defect Repair of Oral Cancer Aided by Mixed Reality Technology Based on UE5 Engine","Inclusion Criteria:\n\n1. Definite pathological diagnosis of oral cancer before surgery;\n2. Defects suitable for free flap reconstruction;\n3. Patients have signed the informed consent form and are willing to cooperate with postoperative follow-up.\n\nExclusion Criteria:\n\n\\- Poor general condition, evaluated as unable to tolerate surgical treatment.\n\n-Exclusion Criteria (After Enrollment)\n\nSubjects who have been enrolled in this trial will be excluded if they meet any of the following conditions:\n\n1. Violation of important inclusion criteria;\n2. Subjects did not receive surgical treatment;\n3. No observation data after randomization. Withdrawal Criteria Withdrawal of subjects from the trial refers to cases where enrolled subjects are determined by the investigator to withdraw from the trial due to conditions that make it inappropriate to continue the trial. In accordance with the informed consent form, subjects have the right to withdraw from the trial midway. Subjects who do not explicitly propose to withdraw but stop receiving treatment and tests and are lost to follow-up are also considered \"withdrawn\" (or \"lost to follow-up\"). The reason for withdrawal should be understood and recorded as much as possible, such as: poor subjective curative effect; inability to tolerate certain adverse reactions; inability to continue participating in the clinical study due to personal reasons; economic factors; or lost to follow-up without stating the reason.\n\n(1) Aggravation or deterioration of the condition during the trial that requires emergency measures; (2) Occurrence of certain comorbidities, complications or special physiological changes in subjects during the trial, making it inappropriate to continue participating in the trial; (3) Voluntary withdrawal by the subject.\n\nData Handling of Withdrawn Subjects\n\nRegardless of the reason, the complete clinical data of subjects who withdraw from the trial shall be retained. For all withdrawn subjects, the trial conclusion form and the reason for withdrawal shall be filled in the case report form (CRF). Generally, there are 6 types of reasons: occurrence of adverse events (including adverse drug reactions and allergic reactions), lack of efficacy (deterioration of condition or occurrence of complications), violation of the trial protocol (including poor compliance), lost to follow-up (including voluntary withdrawal by the patient), termination by the sponsor, or others.",{"count":56,"type":21},30,[58],"NA","The objective of this exploratory clinical trial is to apply Unreal Engine 5 (UE5)-based Mixed Reality (MR) technology to achieve real-time stereoscopic visualization of surgical planning, personalized free flap harvest and defect reconstruction, accurate oral cancer resection, and precise morphological and volumetric matching of the reconstructed free flap to the defect site.\n\nResearchers adopted a parallel controlled design, with participants randomized into three groups: Experimental Group 1 (undergoing Mixed Reality \\[MR\\] technology-assisted surgery), Experimental Group 2 (undergoing virtual surgical guide-assisted surgery), and Control Group (undergoing conventional surgery). A total of 30 participants will be recruited, with 10 cases in each group.\n\nThe primary purpose is to confirm the effectiveness of MR technology in assisting oral cancer resection, free flap design, harvest, and defect reconstruction. Allocation concealment will be implemented via the sealed envelope method.",[61,62,63,29,64],"Tongue Squamous Cell Carcinoma","Mixed Reality","Virtual Surgical Planning","Oral Cancer",[62,66,67,68,69,29,63,64],"tongue reconstruction","Unreal Engine 5","Glossectomy","Surgical guide","2026-03-18",{"date":72,"type":39},"2026-03-20",{"date":74,"type":21},"2026-04-01",{"date":76,"type":21},"2027-10-01",{"name":78,"class":46},"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University"]